Recombinant Cynomolgus HVEM/TNFRSF14 Fc Chimera Protein

R&D Systems, part of Bio-Techne | Catalog # 9197-HV

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
9197-HV-100
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

XP_005545061

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all HVEM/TNFRSF14 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived cynomolgus monkey HVEM/TNFRSF14 protein
Cynomolgus Monkey HVEM/TNFRSF14
(Pro37-Val203)
Accession # XP_005545061		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Pro37

Predicted Molecular Mass

44 kDa

SDS-PAGE

56-63 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Cynomolgus Monkey HVEM/TNFRSF14 Fc Chimera is coated at 2 µg/mL (100 μL/well), biotinylated recombinant mouse BTLA Fc Chimera binds with a typical ED50 of 150-750 ng/mL.

Scientific Data Images for Recombinant Cynomolgus HVEM/TNFRSF14 Fc Chimera Protein

Recombinant Cynomolgus HVEM/TNFRSF14 Fc Chimera Protein Bioactivity

Recombinant Cynomolgus HVEM/TNFRSF14 Fc Chimera Protein Bioactivity

When Recombinant Cymomologus HVEM/TNFRSF14 Fc Chimera (Catalog # 9197-HV) is coated at 2 μg/mL, Recombinant Biotinylated Mouse BTLA Fc Chimera binds with a typical ED50 of 150-750 ng/mL.

Formulation, Preparation and Storage

9197-HV
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 500 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: HVEM/TNFRSF14

HVEM (herpesvirus entry mediator), also known as TNFRSF14 and CD270, is a type I membrane protein in the TNF receptor superfamily, and it can both promote and inhibit T cell activity (1). Mature cynomolgous HVEM consists of a 171 amino acid (aa) extracellular domain (ECD) with three cysteine-rich domains (CRD), a 24 aa transmembrane segment, and a 42 aa cytoplasmic tail with a TRAF interaction domain (2, 3). Within the ECD, cynomolgous HVEM shares 88%, 54%, and 54% aa sequence identity with human, mouse, and rat HVEM, respectively. HVEM is highly expressed on naïve CD4+ T cells, CD8+ T memory cells, regulatory T cells, dendritic cells, monocytes, and neutrophils (4-8). Its expression declines during effector T cell activation but is up-regulated during Treg activation (4, 5). HVEM functions as a receptor for BTLA, CD160, LIGHT/TNFSF14, and Lymphotoxin-a (4, 9-12). Ligation of HVEM by LIGHT triggers T cell, monocyte, and neutrophil activation (8, 10) and contributes to Th1 inflammation and cardiac allograft rejection (13, 14). In contrast, HVEM binding to CD160 or BTLA suppresses T cell and dendritic cell activation (4, 7, 9, 10) and dampens intestinal inflammation (15). HVEM enhances the development of CD8+ T cell memory and Treg function (5, 6). It is additionally expressed on intestinal epithelial cells, where its binding by intraepithelial lymphocyte (IEL) expressed CD160 promotes epitheilal integrity and host defense (16). The herpesvirus envelope glycoprotein gD, which binds HVEM to initiate membrane fusion, can antagonize both BTLA and LIGHT binding (2, 9, 11).

References

  1. del Rio, M.L. et al. (2010) J. Leukoc. Biol. 87:223.
  2. Montgomery, R.I. et al. (1996) Cell 87:427.
  3. Hsu, H. et al. (1997) J. Biol. Chem. 272:13471.
  4. Sedy, J. R. et al. (2005) Nat. Immunol. 6:90.
  5. Tao, R. et al. (2008) J. Immunol. 180:6649.
  6. Steinberg, M.W. et al. (2013) PLoS One 8:e77992.
  7. de Trez, C. et al. (2008) J. Immunol. 180:238.
  8. Heo, S.K. et al. (2006) J. Leukoc. Biol. 79:330.
  9. Gonzalez, L.C. et al. (2005) Proc. Natl. Acad Sci. USA 102:1116.
  10. Cai, G. et al. (2008) Nat. Immunol. 9:176.
  11. Mauri, D.N. et al. (1998) Immunity 8:21.
  12. Harrop, J.A. et al. (1998) J. Biol. Chem. 273:27548.
  13. Wang, J. et al. (2005) J. Immunol. 174:8173.
  14. Ye, Q. et al. (2002) J. Exp. Med. 195:795.
  15. Steinberg, M.W. et al. (2008) J. Exp. Med. 205:1463.
  16. Shui, J.W. et al. (2012) Nature 488:222.

Long Name

Herpesvirus Entry Mediator

Alternate Names

ATAR, CD270, LIGHTR, TNFRSF14

Entrez Gene IDs

8764 (Human); 230979 (Mouse); 102137807 (Cynomolgus Monkey)

Gene Symbol

TNFRSF14

UniProt

XP_005545061

Additional HVEM/TNFRSF14 Products

Product Documents for Recombinant Cynomolgus HVEM/TNFRSF14 Fc Chimera Protein

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Cynomolgus HVEM/TNFRSF14 Fc Chimera Protein

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.